Depression

Depression is a disabling condition and the third most common reason for consulting a GP in the UK. Depression is the second cause of disability worldwide in 2020. Treatment-resistant depression defined as people with major depressive disorder (MDD) who do not respond adequately to two courses of appropriate antidepressant medication within a certain time. A multicentre study found that around 50% of depressed patients were considered treatment-resistant after two consecutive courses of treatment with antidepressants.

Many people worldwide are suffering from major depression and every day is a battle in confronting the symptoms that comes with this mental condition. An additional burden that people suffering from major depression are facing is that the medications that they are on are not having the desired effect or no effect at all making patients treatment-resistant. 

This is a frustrating scenario for many people who are suffering from major depression. Another major disadvantage is that most antidepressants that are available take weeks or months to start working and for some patients do not work at all. This is failing patients who are at risk of harming themselves through self-harm and suicide.

READ MORE

Spravato® is the new nasal spray that has been approved by the Food and Drug Administration in the United States and also approved by the EC in Europe.

This spray was developed by Janssen Pharmaceuticals to serve those who are currently suffering from major depression and patients who have thoughts of suicide and patients who are treatment-resistant to other treatments for major depression. This new nasal spray is for those who are treatment-resistant to standard drugs such as antidepressants.

Spravato® works on the glutamate the brain neurotransmitter that uplifts the mood state you will be in. Other antidepressants work on serotonin and norepinephrine, these two neurotransmitters then work on the glutamate neurotransmitter.

Spravato® works smarter and faster and targets the glutamate straight away. Spravato is a brand new medication nasal spray and major step forward in three decades since Prozac wooed the depression market and prescribed by psychiatrists all over the globe.

Spravato® is a new antidepressant spray that is indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to a severe depressive episode.

Spravato® is uniquely provided at Ciconia Recovery London. It is advised to be taken by a nasal (nose) spray device.

At Ciconia Recovery, we will show you how to use Spravato® properly.

You will spray the medicine into your nose yourself. At Ciconia Recovery, the doctor will decide if you need one, two or three nasal spray devices and how often you should come to the clinic for the medicine.